We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

174 hedge funds and large institutions have $2.46B invested in Sage Therapeutics in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 74 increasing their positions, 52 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 52

2.25% more ownership

Funds ownership: 102.94% → 105.18% (+2.2%)

8% less funds holding

Funds holding: 190 → 174 (-16)

20% less capital invested

Capital invested by funds: $3.06B → $2.46B (-$599M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

35% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 37

39% less call options, than puts

Call options by funds: $66.5M | Put options by funds: $109M

Holders
174
Holders Change
-16
Holders Change %
-8.42%
% of All Funds
4.34%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
24
Increased
74
Reduced
52
Closed
37
Calls
$66.5M
Puts
$109M
Net Calls
-$42.7M
Net Calls Change
-$67.5M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$88.6M
2
Bank of New York Mellon
Bank of New York Mellon
New York
+$56.9M
3
BBA
Baker Bros. Advisors
New York
+$15.5M
4
BB
BB Biotech
Switzerland
+$14.5M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$13.3M

Top Sellers

Rank Fund Capital Flow
1
MWNA
Marshall Wace North America
New York
-$22.4M
2
Deutsche Bank
Deutsche Bank
Germany
-$22.1M
3
PAI
Palo Alto Investors
California
-$19.3M
4
Jennison Associates
Jennison Associates
New York
-$16.9M
5
Barclays
Barclays
United Kingdom
-$11.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
QIM
176
Quantitative Investment Management
Virginia
– -$4.65M -58,400 Closed
GTC
177
Ghost Tree Capital
New York
– -$3.93M -50,000 Closed
RCM
178
Ratan Capital Management
Florida
– -$3.98M -50,000 Closed
SC
179
Samlyn Capital
New York
– -$3.77M -47,300 Closed
Susquehanna International Group
180
Susquehanna International Group
Pennsylvania
– -$3.54M -45,032 Closed
FHAM
181
Folger Hill Asset Management
New York
– -$3.3M -41,471 Closed
SGH
182
Sivik Global Healthcare
Connecticut
– -$1.59M -20,000 Closed
Handelsbanken Fonder
183
Handelsbanken Fonder
Sweden
– -$1.11M -14,000 Closed
JG
184
Jefferies Group
New York
– -$1.11M -14,000 Closed
SAM
185
Sectoral Asset Management
Quebec, Canada
– -$972K -12,199 Closed
DCM
186
Driehaus Capital Management
Illinois
– -$887K -11,139 Closed
LCG
187
Lisanti Capital Growth
New York
– -$886K -11,123 Closed
SSA
188
Schonfeld Strategic Advisors
New York
– -$684K -8,586 Closed
DTL
189
Dynamic Technology Lab
Singapore
– -$598K -7,513 Closed
ACM
190
Atika Capital Management
New York
– -$550K -7,000 Closed
AR
191
Advisory Research
Illinois
– -$476K -5,975 Closed
Stifel Financial
192
Stifel Financial
Missouri
– -$401K -4,998 Closed
DIA
193
Denver Investment Advisors
Colorado
– -$351K -4,403 Closed
WC
194
Wexford Capital
Florida
– -$350K -4,400 Closed
FRM
195
Fox Run Management
Connecticut
– -$271K -3,400 Closed
Brown Advisory
196
Brown Advisory
Maryland
– -$248K -3,111 Closed
TSS
197
Two Sigma Securities
New York
– -$245K -3,081 Closed
Parallax Volatility Advisers
198
Parallax Volatility Advisers
California
– -$235K -2,996 Closed
Two Sigma Advisers
199
Two Sigma Advisers
New York
– -$223K -2,800 Closed
COPPSERS
200
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$211K -2,648 Closed
5 6 7
8
9

SAGE Hedge Fund Activity: Q3 2017 in Review

174 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2017, worth a combined $2.46B — down 20% from $3.06B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of SAGE and 24 opened new positions — a net loss of 13 holders — while 52 trimmed existing stakes and 74 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $88.6M. The largest seller was Marshall Wace North America, cutting an estimated $22.4M.

  • 174 institutional investors held Sage Therapeutics (SAGE) as of Q3 2017, down from 190 in Q2 2017.
  • Funds reported $2.46B of Sage Therapeutics stock for Q3 2017, down 20% quarter-over-quarter.
  • 24 funds opened new Sage Therapeutics positions in Q3 2017 and 37 closed out, a net change of -13 holders.
  • The largest Sage Therapeutics buyer in Q3 2017 was T. Rowe Price Associates, an estimated $88.6M added.
  • The largest Sage Therapeutics seller in Q3 2017 was Marshall Wace North America, an estimated $22.4M sold.

Based on aggregated 13F filings for Q3 2017.